AG-120
Title | Journal |
---|---|
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. | The New England journal of medicine 20180621 |
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. | Clinical lymphoma, myeloma & leukemia 20160801 |
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. | Nature 20091210 |